Canopus BioPharma Incorporated
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and chan… Read more
Canopus BioPharma Incorporated (CBIA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of May 2023: 0.849x
Based on the latest financial reports, Canopus BioPharma Incorporated (CBIA) has a cash flow conversion efficiency ratio of 0.849x as of May 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-157.02K) by net assets ($-184.96K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Canopus BioPharma Incorporated - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Canopus BioPharma Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Canopus BioPharma Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Canopus BioPharma Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Snoogoo Corp
PINK:SGOO
|
-0.001x |
|
Medican Enterprises
PINK:MDCN
|
-0.681x |
|
SFLMaven Corp
PINK:SFLM
|
0.000x |
|
Avix Technologies Inc
PINK:AVIX
|
0.004x |
|
Nexity Financial Corporation
PINK:NXTYQ
|
N/A |
|
Greyson International Inc
PINK:GYSN
|
0.003x |
|
Newron Sport
PINK:NSPT
|
0.075x |
|
Outback Oil & Mineral Exploration Corp
PINK:OUTB
|
N/A |
Annual Cash Flow Conversion Efficiency for Canopus BioPharma Incorporated (2013–2022)
The table below shows the annual cash flow conversion efficiency of Canopus BioPharma Incorporated from 2013 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-08-31 | $-13.28K | $-6.18K | 0.466x | +113.11% |
| 2014-08-31 | $-542.70K | $1.93 Million | -3.552x | -1821.55% |
| 2013-08-31 | $-2.64 Million | $-544.02K | 0.206x | -- |